|
Indications & Dosage
INDICATIONS AND USAGE
Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). In patients with CHD or at high risk of CHD, ZOCOR can be started simultaneously with diet. Text Continues Below
Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, ZOCOR is indicated to:
Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke.
Reduce the need for coronary and non-coronary revascularization procedures. Patients with Hypercholesterolemia Requiring Modifications of Lipid Profiles ZOCOR is indicated to:
Reduce elevated total-C, LDL-C, Apo B, and TG, and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb 4 ).
Treat patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Treat patients with primary dysbetalipoproteinemia (Fredrickson type lll hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e. g., LDL apheresis) or if such treatments are unavailable. Classification of Hyperlipoproteinemias Lipid Lipoproteins Elevations Type elevated major minor
I (rare) chylomicrons TG C IIa LDL C —
IIb LDL, VLDL C TG III (rare) IDL C/ TG —
IV VLDL TG C
V (rare) chylomicrons, VLDL TG C C = cholesterol, TG = triglycerides, LDL = low-density lipoprotein, VLDL = very-low-density lipoprotein, IDL = intermediate-density lipoprotein. Page: 1 | 2 | 3 | 4 | Next >>
|
.gif)
